Your browser doesn't support javascript.
loading
Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease.
Garcia-Gomez, Antonio; Li, Tianlu; de la Calle-Fabregat, Carlos; Rodríguez-Ubreva, Javier; Ciudad, Laura; Català-Moll, Francesc; Godoy-Tena, Gerard; Martín-Sánchez, Montserrat; San-Segundo, Laura; Muntión, Sandra; Morales, Xabier; Ortiz-de-Solórzano, Carlos; Oyarzabal, Julen; San José-Enériz, Edurne; Esteller, Manel; Agirre, Xabier; Prosper, Felipe; Garayoa, Mercedes; Ballestar, Esteban.
Afiliação
  • Garcia-Gomez A; Epigenetics and Immune Disease Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, 08916, Badalona, Barcelona, Spain. nonogarcia85@gmail.com.
  • Li T; Chromatin and Disease Group, Cancer Epigenetics and Biology Programme (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), 08908, L'Hospitalet de Llobregat, Barcelona, Spain. nonogarcia85@gmail.com.
  • de la Calle-Fabregat C; Epigenetics and Immune Disease Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, 08916, Badalona, Barcelona, Spain.
  • Rodríguez-Ubreva J; Chromatin and Disease Group, Cancer Epigenetics and Biology Programme (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), 08908, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Ciudad L; Epigenetics and Immune Disease Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, 08916, Badalona, Barcelona, Spain.
  • Català-Moll F; Chromatin and Disease Group, Cancer Epigenetics and Biology Programme (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), 08908, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Godoy-Tena G; Epigenetics and Immune Disease Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, 08916, Badalona, Barcelona, Spain.
  • Martín-Sánchez M; Chromatin and Disease Group, Cancer Epigenetics and Biology Programme (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), 08908, L'Hospitalet de Llobregat, Barcelona, Spain.
  • San-Segundo L; Epigenetics and Immune Disease Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, 08916, Badalona, Barcelona, Spain.
  • Muntión S; Chromatin and Disease Group, Cancer Epigenetics and Biology Programme (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), 08908, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Morales X; Epigenetics and Immune Disease Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, 08916, Badalona, Barcelona, Spain.
  • Ortiz-de-Solórzano C; Chromatin and Disease Group, Cancer Epigenetics and Biology Programme (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), 08908, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Oyarzabal J; Epigenetics and Immune Disease Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, 08916, Badalona, Barcelona, Spain.
  • San José-Enériz E; Centro de Investigación del Cáncer, IBMCC (Universidad de Salamanca-CSIC) and Hospital Universitario de Salamanca-IBSAL, 37007, Salamanca, Spain.
  • Esteller M; Centro de Investigación del Cáncer, IBMCC (Universidad de Salamanca-CSIC) and Hospital Universitario de Salamanca-IBSAL, 37007, Salamanca, Spain.
  • Agirre X; Centro de Investigación del Cáncer, IBMCC (Universidad de Salamanca-CSIC) and Hospital Universitario de Salamanca-IBSAL, 37007, Salamanca, Spain.
  • Prosper F; Imaging Platform, Center for Applied Medical Research (CIMA), University of Navarra, IDISNA, Ciberonc, 31008, Pamplona, Spain.
  • Garayoa M; Imaging Platform, Center for Applied Medical Research (CIMA), University of Navarra, IDISNA, Ciberonc, 31008, Pamplona, Spain.
  • Ballestar E; Small Molecule Discovery Platform, Molecular Therapeutics Program, Center for Applied Medical Research (CIMA), University of Navarra, 31008, Pamplona, Spain.
Nat Commun ; 12(1): 421, 2021 01 18.
Article em En | MEDLINE | ID: mdl-33462210
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Ósseas / Metilação de DNA / Inibidores Enzimáticos / Células-Tronco Mesenquimais / Mieloma Múltiplo / Antineoplásicos Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Aged80 Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Ósseas / Metilação de DNA / Inibidores Enzimáticos / Células-Tronco Mesenquimais / Mieloma Múltiplo / Antineoplásicos Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Aged80 Idioma: En Ano de publicação: 2021 Tipo de documento: Article